Acute Kidney Injury in Cirrhosis

被引:462
作者
Garcia-Tsao, Guadalupe [1 ,2 ]
Parikh, Chirag R. [2 ,3 ]
Viola, Antonella [1 ,2 ,4 ]
机构
[1] Yale Univ, Sch Med, Sect Digest Dis, New Haven, CT 06510 USA
[2] VA Connecticut Healthcare Syst, West Haven, CT USA
[3] Yale Univ, Sch Med, Nephrol Sect, New Haven, CT USA
[4] Univ Bologna, Dept Clin Med, I-40126 Bologna, Italy
关键词
D O I
10.1002/hep.22605
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Acute renal failure (ARF), recently renamed acute kidney injury (AKI), is a relatively frequent problem, occurring in approximately 20% of hospitalized patients with cirrhosis. Although serum creatinine may underestimate the degree of renal dysfunction in cirrhosis, measures to diagnose and treat AKI should be made in patients in whom serum creatinine rises abruptly by 0.3 mg/dL or more (>= 26.4 mu mol/L) or increases by 150% or more (1.5-fold) from baseline. The most common causes of ARF (the term is used interchangeably with AKI) in cirrhosis are prerenal azotemia (volume-responsive prerenal AKI), acute tubular necrosis, and hepatorenal syndrome (HRS), a functional type of prerenal AKI exclusive of cirrhosis that does not respond to volume repletion. Because of the progressive vasodilatory state of cirrhosis that leads to relative hypovolemia and decreased renal blood flow, patients with decompensated cirrhosis are very susceptible to developing AKI with events associated with a decrease in effective arterial blood volume. HRS can occur spontaneously but is more frequently precipitated by events that worsen vasodilatation, such as spontaneous bacterial peritonitis. Conclusion: Specific therapies of AKI depend on the most likely cause and mechanism. Vasoconstrictors are useful bridging therapies in HRS. Ultimately, liver transplantation is indicated in otherwise reasonable candidates in whom AKI does not resolve with specific therapy. (HEPATOLOGY 2008;48:2064-2077.)
引用
收藏
页码:2064 / 2077
页数:14
相关论文
共 86 条
[41]   The hyperdynamic circulation of chronic liver diseases: From the patient to the molecule [J].
Iwakiri, Y ;
Groszmann, RJ .
HEPATOLOGY, 2006, 43 (02) :S121-S131
[42]   Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study [J].
Kiser, TH ;
Fish, DN ;
Obritsch, MD ;
Jung, R ;
MacLaren, R ;
Parikh, CR .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 (09) :1813-1820
[43]   THE CARDIAC OUTPUT AT REST IN LAENNECS CIRRHOSIS [J].
KOWALSKI, HJ ;
ABELMANN, WH .
JOURNAL OF CLINICAL INVESTIGATION, 1953, 32 (10) :1025-1033
[44]   Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome [J].
Krag, Aleksander ;
Moller, Soren ;
Henriksen, Jens H. ;
Holstein-Rathlou, Niels-Henrik ;
Larsen, Fin Stolze ;
Bendtsen, Flemming .
HEPATOLOGY, 2007, 46 (06) :1863-1871
[45]   Vasoconstrictor therapy for the hepatorenal syndrome [J].
Lim, Joseph K. ;
Groszmann, Roberto J. .
GASTROENTEROLOGY, 2008, 134 (05) :1608-1611
[46]   ACUTE TUBULAR-NECROSIS IN HEPATORENAL-SYNDROME - AN ELECTRON-MICROSCOPY STUDY [J].
MANDAL, AK ;
LANSING, M ;
FAHMY, A .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1982, 2 (03) :363-374
[47]   Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome:: A randomized study [J].
Martin-Llahi, Marta ;
Pepin, Marie-Noelle ;
Guevara, Monica ;
Diaz, Fernando ;
Torre, Aldo ;
Monescillo, Alberto ;
Soriano, German ;
Terra, Carlos ;
Fabrega, Emilio ;
Arroyo, Vicente ;
Rodes, Juan ;
Gines, Pere .
GASTROENTEROLOGY, 2008, 134 (05) :1352-1359
[48]   Brief communication: Glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantation [J].
McGuire, Brendan M. ;
Julian, Bruce A. ;
Bynon, J. Steve, Jr. ;
Cook, William J. ;
King, Steven J. ;
Curtis, John J. ;
Accortt, Neil A. ;
Eckhoff, Devin E. .
ANNALS OF INTERNAL MEDICINE, 2006, 144 (10) :735-741
[49]   Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury [J].
Mehta, Ravindra L. ;
Kellum, John A. ;
Shah, Sudhir V. ;
Molitoris, Bruce A. ;
Ronco, Claudio ;
Warnock, David G. ;
Levin, Adeera .
CRITICAL CARE, 2007, 11 (02)
[50]   Transjugular intrahepatic portosystemic shunt for cirrhosis and ascites:: Effects in patients with organic or functional renal failure [J].
Michl, P ;
Gülberg, V ;
Bilzer, M ;
Waggershauser, T ;
Gerbes, AL .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2000, 35 (06) :654-658